Universitat Autònoma

Jul 26, 2023 | thelancet.com | Patricia Pozo-Rosich |Universitat Autònoma |Jessica Ailani |Messoud Ashina

Summary In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. We did this randomised, double-blind, placebo-controlled, phase 3 trial at 142 clinical research sites across the USA, the UK, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, and Taiwan.

Apr 3, 2023 | ashpublications.org | Friedrich-Alexander-Universität Erlangen-Nürnberg |Universitat Autònoma |von Bergwelt-Baildon

TO THE EDITOR: Despite the curative potential of chimeric antigen receptor (CAR) T cells, a significant number of patients fail to respond, underlining the need for precise patient monitoring.1-3 Currently, assessing responses in real-world settings is mainly based on radiography at 1 and 3 months after CAR T-cell infusion.4-6 However, because disease progression is rapid in heavily pretreated patients, earlier detection of treatment failure would be favorable, so that salvage treatment can...

Feb 20, 2023 | n.neurology.org | Richard Lipton |Universitat Autònoma |Patricia Pozo-Rosich

AbstractBackground and Objectives The oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. Methods In this phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (ADVANCE), adults with 4–14 migraine days per month received atogepant (10, 30, or 60 mg) once daily or placebo.